438 related articles for article (PubMed ID: 34144233)
1. RASopathies: The musculoskeletal consequences and their etiology and pathogenesis.
Fowlkes JL; Thrailkill KM; Bunn RC
Bone; 2021 Nov; 152():116060. PubMed ID: 34144233
[TBL] [Abstract][Full Text] [Related]
2. Craniosynostosis in patients with RASopathies: Accumulating clinical evidence for expanding the phenotype.
Ueda K; Yaoita M; Niihori T; Aoki Y; Okamoto N
Am J Med Genet A; 2017 Sep; 173(9):2346-2352. PubMed ID: 28650561
[TBL] [Abstract][Full Text] [Related]
3. The RASopathies: Biology, genetics and therapeutic options.
Longo JF; Carroll SL
Adv Cancer Res; 2022; 153():305-341. PubMed ID: 35101235
[TBL] [Abstract][Full Text] [Related]
4. A review of craniofacial and dental findings of the RASopathies.
Cao H; Alrejaye N; Klein OD; Goodwin AF; Oberoi S
Orthod Craniofac Res; 2017 Jun; 20 Suppl 1(Suppl 1):32-38. PubMed ID: 28643916
[TBL] [Abstract][Full Text] [Related]
5. The RASopathies: from pathogenetics to therapeutics.
Hebron KE; Hernandez ER; Yohe ME
Dis Model Mech; 2022 Feb; 15(2):. PubMed ID: 35178568
[TBL] [Abstract][Full Text] [Related]
6. The RASopathies.
Rauen KA
Annu Rev Genomics Hum Genet; 2013; 14():355-69. PubMed ID: 23875798
[TBL] [Abstract][Full Text] [Related]
7. Recent developments in neurofibromatoses and RASopathies: management, diagnosis and current and future therapeutic avenues.
Rauen KA; Huson SM; Burkitt-Wright E; Evans DG; Farschtschi S; Ferner RE; Gutmann DH; Hanemann CO; Kerr B; Legius E; Parada LF; Patton M; Peltonen J; Ratner N; Riccardi VM; van der Vaart T; Vikkula M; Viskochil DH; Zenker M; Upadhyaya M
Am J Med Genet A; 2015 Jan; 167A(1):1-10. PubMed ID: 25393061
[TBL] [Abstract][Full Text] [Related]
8. RAS signalling in energy metabolism and rare human diseases.
Dard L; Bellance N; Lacombe D; Rossignol R
Biochim Biophys Acta Bioenerg; 2018 Sep; 1859(9):845-867. PubMed ID: 29750912
[TBL] [Abstract][Full Text] [Related]
9. Autism traits in the RASopathies.
Adviento B; Corbin IL; Widjaja F; Desachy G; Enrique N; Rosser T; Risi S; Marco EJ; Hendren RL; Bearden CE; Rauen KA; Weiss LA
J Med Genet; 2014 Jan; 51(1):10-20. PubMed ID: 24101678
[TBL] [Abstract][Full Text] [Related]
10. [New insight of craniofacial and oral findings of the RASopathies].
Cao HT; Yang YJ; Zheng Q; Shi B; Li CH
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Dec; 53(12):858-861. PubMed ID: 30522213
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in RASopathies.
Aoki Y; Niihori T; Inoue S; Matsubara Y
J Hum Genet; 2016 Jan; 61(1):33-9. PubMed ID: 26446362
[TBL] [Abstract][Full Text] [Related]
12. RASopathies: Dermatologists' viewpoints.
Palit A; Inamadar AC
Indian J Dermatol Venereol Leprol; 2022; 88(4):452-463. PubMed ID: 35138057
[TBL] [Abstract][Full Text] [Related]
13. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of Growth Failure in Rasopathies.
Aftab S; Dattani MT
Pediatr Endocrinol Rev; 2019 May; 16(Suppl 2):447-458. PubMed ID: 31115196
[TBL] [Abstract][Full Text] [Related]
15. Rasopathies - dysmorphic syndromes with short stature and risk of malignancy.
Cizmarova M; Kostalova L; Pribilincova Z; Lasabova Z; Hlavata A; Kovacs L; Ilencikova D
Endocr Regul; 2013 Oct; 47(4):217-22. PubMed ID: 24156711
[TBL] [Abstract][Full Text] [Related]
16. The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway.
Tajan M; Paccoud R; Branka S; Edouard T; Yart A
Endocr Rev; 2018 Oct; 39(5):676-700. PubMed ID: 29924299
[TBL] [Abstract][Full Text] [Related]
17. The RASopathies as an example of RAS/MAPK pathway disturbances - clinical presentation and molecular pathogenesis of selected syndromes.
Bezniakow N; Gos M; Obersztyn E
Dev Period Med; 2014; 18(3):285-96. PubMed ID: 25182392
[TBL] [Abstract][Full Text] [Related]
18. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
Rauen KA; Schoyer L; Schill L; Stronach B; Albeck J; Andresen BS; Cavé H; Ellis M; Fruchtman SM; Gelb BD; Gibson CC; Gripp K; Hefner E; Huang WYC; Itkin M; Kerr B; Linardic CM; McMahon M; Oberlander B; Perlstein E; Ratner N; Rogers L; Schenck A; Shankar S; Shvartsman S; Stevenson DA; Stites EC; Stork PJS; Sun C; Therrien M; Ullian EM; Widemann BC; Yeh E; Zampino G; Zenker M; Timmer W; McCormick F
Am J Med Genet A; 2018 Dec; 176(12):2924-2929. PubMed ID: 30302932
[TBL] [Abstract][Full Text] [Related]
19. Objective studies of the face of Noonan, Cardio-facio-cutaneous, and Costello syndromes: A comparison of three disorders of the Ras/MAPK signaling pathway.
Allanson JE
Am J Med Genet A; 2016 Oct; 170(10):2570-7. PubMed ID: 27155212
[TBL] [Abstract][Full Text] [Related]
20. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
Rauen KA; Alsaegh A; Ben-Shachar S; Berman Y; Blakeley J; Cordeiro I; Elgersma Y; Evans DG; Fisher MJ; Frayling IM; George J; Huson SM; Kerr B; Khire U; Korf B; Legius E; Messiaen L; van Minkelen R; Nampoothiri S; Ngeow J; Parada LF; Phadke S; Pillai A; Plotkin SR; Puri R; Raji A; Ramesh V; Ratner N; Shankar SP; Sharda S; Tambe A; Vikkula M; Widemann BC; Wolkenstein P; Upadhyaya M
Am J Med Genet A; 2019 Jun; 179(6):1091-1097. PubMed ID: 30908877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
